Drugs that contain Aliskiren Hemifumarate
1. Tekturna patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5559111 | NODEN PHARMA | δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides |
Jul, 2018
(5 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5559111 (Pediatric) | NODEN PHARMA | δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides |
Jan, 2019
(5 years ago) | |
| US8617595 | NODEN PHARMA | Galenic formulations of organic compounds |
Feb, 2026
(1 year, 9 months from now) | |
|
US8617595 (Pediatric) | NODEN PHARMA | Galenic formulations of organic compounds |
Aug, 2026
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 05, 2012 |
NCE-1 date: 06 March, 2011
Market Authorisation Date: 05 March, 2007
Treatment: Treatment of hypertension
Dosage: TABLET;ORAL
How can I launch a generic of TEKTURNA before it's drug patent expiration?
More Information on Dosage
TEKTURNA family patents
